Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript

Cochlear reported FY26 sales revenue up 2% in constant currency to $2.3B and underlying net profit of $322M. The company said results were below the expectations set last August, though they were at the upper end of the guidance revised in April, with H2 revenue up 6%. Overall tone is cautious given the miss vs initial expectations despite relatively solid growth and guidance positioning.

Analysis

This reads less like a one-off miss and more like a reminder that the core end-market is still mature: when the replacement/upgrade cycle is doing the heavy lifting, any slowdown in new adult adoption disproportionately pressures the valuation multiple. The immediate loser is CHEOY itself, but the bigger second-order effect is on the premium embedded in the stock for recurring installed-base monetization; if the market concludes growth is drifting toward low-single-digit software-like stability without software-like retention economics, the multiple can compress faster than the earnings line.

The competitive spillover is more interesting than the company-specific print. If adult developed-market penetration remains soft, hearing-aid platforms and broader audiology players such as Sonova and Demant can look relatively better on ease-of-adoption and channel breadth, even if they are not direct implant substitutes for every patient. Conversely, clinics and distributors may push more conservative treatment sequencing, which can delay implant conversion and elongate the sales cycle for everyone in the category.

Near term, the stock is vulnerable to another round of estimate cuts if the next data points confirm that FY27 is starting from a weak base; that’s a weeks-to-3-months risk. The structural question is whether the installed base can still deliver enough processor upgrades and adjacent revenue to justify a premium medtech multiple over 6-18 months. What would falsify the bearish read: a clear re-acceleration in developed adult growth, plus evidence that processor replacement rates are holding above the recent run-rate rather than being pulled forward and normalized away.

Key Decisions for Investors

• Avoid chasing CHEOY into post-earnings strength; if the shares gap up, use it to fade into any move that prices in a return to mid/high-single-digit growth without evidence of channel re-acceleration.
• Relative-value trade: short CHEOY vs long Sonova (SONVY) or Demant on a 1-3 month horizon if you want exposure to the same hearing-care demand pool but with less dependence on implant conversion; thesis breaks if CHEOY shows developed-adult reacceleration in the next update.